- 目次
-
CBC Co., Ltd. (Head Office: Chuo-ku, Tokyo; President: Masataro Doi; hereinafter “CBC”), Formiica Pharmaceuticals Pte. Ltd. (Head Office: Singapore; CEO: Renaat Janssen; hereinafter “Formiica”) and Nippon Kayaku Co., Ltd. (Head Office: Chiyoda-ku, Tokyo; President & CEO: Shigeyuki Kawamura; hereinafter “Nippon Kayaku”) have agreed to jointly establish a joint venture for the purpose of in-licensing pharmaceutical products into Asia including Japan and/or Oceania, and hereby announce that the three companies have executed a Shareholders Agreement for the joint venture as of August 8, 2025.
Purpose of Establishing the Joint Venture
This joint venture will be established through joint investment by CBC, Formiica and Nippon Kayaku, with its base in Singapore. Its main purpose is to in-licensing pharmaceutical products developed and owned by other companies, and to sublicense such products to countries in Asia and/or Oceania, including Japan.
By leveraging CBC's network and respective companies’ strength, CBC expect the growth of joint venture, and which lead to strengthening CBC’s Pharmaceutical business.
Future Outlook
Following the execution of the agreement, we will promptly proceed with the establishment of the joint venture and accelerate the consideration and negotiation of promising in-licensing candidates.
[About Formiica Pharmaceuticals Pte. Ltd.]
Formiica Pharmaceuticals Pte Ltd (“Formiica”) is a Singapore-based holding company incubated by the SEA Healthcare Fund VCC with Wuxi AppTec and UOBVM as sector advisor and investment advisor respectively. Formiica’s vision is to bring innovative and cost-effective medicines to meet the unmet clinical and diverse socioeconomic needs of the key markets in Japan, Australia, Korea and Southeast Asia (“SEA”) through a network of partners across clinical/product development, contract manufacturing and commercialization. Formiica intends to achieve its vision by in-licensing patented medicines that are in late clinical development stage or medicines with marketing authorizations in key pharmaceutical markets such as USA and Europe.
[About Nippon Kayaku Co., Ltd.]
Nippon Kayaku was founded in 1916 as the first industrial explosives manufacturer in Japan. We have developed products to meet the needs of the time by utilizing, combining and transforming our core technologies in the company’s main areas, explosives, dyes, pharmaceuticals and resins. The Nippon Kayaku Group operates in the Mobility & Imaging Business Unit, the Fine Chemicals Business Unit, and the Life Science Business Unit. We will continue to create high-value-added products that are indispensable to the world by concentrating our unique technologies.
In the Pharmaceuticals Business, a part of the Life Science Business Unit, Nippon Kayaku specializes in anticancer drugs and other cancer-related products, handling a range of products from new drugs to biosimilars and generics. We strive to provide trustworthy information crucial for understanding anticancer drugs to medical institutions.
Please visit the company website at “https://www.nipponkayaku.co.jp/english/” for more information